Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 1/12/2021 (updated 4/4/2024)
This handbook is for anyone looking for help or information, and for people who care about them, who may be: Misusing prescription pain medications, using narcotics, heroin, or other opioid drugs; thinking about seeking help for an opioid problem; or Considering medications that help with recovery from opioid use disorder.
Posted 10/23/2020 (updated 4/3/2024)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of BUP-ER 100 mg and 300 mg for the management of moderate-to-severe OUD in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 9/30/2020 (updated 3/29/2024)
This page offers background information and tips for providers to keep in mind while using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.
Posted 9/1/2020 (updated 3/29/2024)
This toolkit is intended to give prescribers a broad overview of medication utilization management techniques and describe ways that prescribers can facilitate patient access to needed medications. It focuses on prescribed medications that are filled by retail pharmacies; it does not cover the processes for methadone or specialty pharmacy products, such as injectable or implantable medications, all of which are commonly covered by a patient’s medical benefit rather than their pharmacy benefit.